March 3, 2026 · Form 4 insider transaction
Fitzgerald Kevin Joseph sold 359 shares of Alnylam Pharmaceuticals, Inc. at $321.58 per share, a transaction worth $115.4K. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 1 day after the transaction.
This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on August 14, 2025.; The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.36 to $321.84. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.